Atrium Therapeutics, Inc. (RNA)
Nasdaq · Healthcare · Biotechnology
$7.97+1.66%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $136M
- 52-week range
- $7.63 – $16.77
- 52-week change
- −46.85%
- EPS (trailing)
- −$5.44
- Next earnings
- Nov 9, 2026
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · atriumtherapeutics.com